Y-Mabs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Y-Mabs Therapeutics reports record revenues and strategic growth initiatives

Y-Mabs Therapeutics demonstrated strong financial performance in Q4 2022, with record revenues and effective cost management.
The company's focus on product development and market expansion, coupled with strategic restructuring, positions it for sustainable growth.
While facing financial challenges and competitive pressures, Y-Mabs Therapeutics has opportunities for portfolio expansion and market penetration.

Y-Mabs Therapeutics Inc achieves record revenue, eyes international expansion

Y-Mabs Therapeutics Inc reported strong performance in Q1 2023, driven by record net product revenue and positive sales trends for DANYELZA.
The company's focus on R&D, commercialization efforts, and strategic partnerships positions it well for future growth and market expansion.
While facing challenges such as market competition and restructuring, Y-Mabs Therapeutics Inc has opportunities to capitalize on its innovative technologies and market presence.
With updated financial guidance and a clear roadmap for product development, the company is poised for continued success and revenue growth in 2023.

Y-Mabs reports robust Q2 earnings, eyes international expansion and label growth

Y-Mabs Therapeutics Inc demonstrated strong financial performance with notable revenue growth for DANYELZA and advancements in their SADA platform.
While facing challenges in competitive dynamics and treatment optimization, the company is strategically positioned for international market expansion and revenue diversification.
Opportunities lie in market penetration strategies, upcoming label expansions, and continued product development efforts, indicating a positive outlook for future growth and innovation.

Y-Mabs Therapeutics reports strong Q3 performance and eyes oncology expansion

Y-Mabs Therapeutics showcased robust financial performance, strong commercial traction for DANYELZA, and promising advancements in the SADA platform.
While facing challenges in scalability and dose optimization, the company's strategic strengths lie in leadership changes, clinical progress, and market penetration.
Opportunities for growth include expanding indications, optimizing treatment protocols, and enhancing visibility through data presentations and partnerships.

Y-mAbs reports strong Q4 earnings, eyes global expansion and program innovations

Y-mAbs Therapeutics showcased robust financial performance in Q4 2023, driven by strong DANYELZA net product sales and revenue growth.
Effective cost management, expansion plans into key markets, and enhanced marketing efforts position the company for continued success.
While facing challenges in managing expenses and addressing analyst inquiries, Y-mAbs has opportunities for growth through international expansion and program innovations.

Y-mAbs reports record DANYELZA sales, eyes global expansion and innovation

Y-mAbs Therapeutics showcased robust financial performance with record DANYELZA sales, underpinned by strategic expansion efforts and progress in clinical programs.
While facing questions on growth strategies and potential seasonality challenges, the company's strong balance sheet and focus on innovation position it well for future success.
By emphasizing responsible capital allocation, global expansion, and advancements in cancer treatment options, Y-mAbs is poised to navigate challenges and seize opportunities for sustained growth.

Y-mAbs Therapeutics reports revenue growth and promising clinical outcomes

Y-mAbs Therapeutics Inc. delivered solid financial performance, strong product sales, and promising clinical trial outcomes in Q2 2024, positioning the company for continued growth.
While facing challenges in managing cash burn and sustaining revenue growth, the company's commitment to innovation and patient care presents opportunities for future success.
With a revised revenue guidance and focus on advancing novel therapies, Y-mAbs Therapeutics Inc. remains dedicated to improving patient lives and driving growth in the biopharmaceutical sector.

Y-Mabs Therapeutics reports mixed Q3 performance with growth opportunities

Y-Mabs Therapeutics faced challenges with declining DANYELZA revenues outside the U.S.
However, the company demonstrated strengths in securing long-term exclusivity and expanding market reach.
Opportunities lie in leveraging partnerships, exploring new targets, and ongoing clinical trials.
Maintaining financial stability and meeting full-year guidance are key priorities for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - January 18, 2023) - Wolf Popper LLP announces that it has filed a class action on behalf of all persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the Securities and Exchange Commission, during the period October 6, 2020 through October 28, 2022 (the "Class Period").

Wolf Popper LLP Announces the Filing of a Class Action Lawsuit Against Y-mAbs Therapeutics, Inc.

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a strategic restructuring plan designed to extend its cash runway and prioritize resources on the commercialization and potential label extension of DANYELZA and development of the SADA (Self-Assembly DisAssembly (“SADA”) PRIT 2-STEP) technology platform. The Company plans to discuss omburtamab at its upcoming Type A meeting with the FDA; however, the Company has assumed a deprioritization of the omburtamab program, including all indications, in designing its restructuring plan and in its estimates for 2023. In addition, the Company plans to deprioritize other pipeline programs, including activities relating to GD2-GD3 Vaccine and CD33 bispecific antibody constructs, as part of the restructuring plan.

Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its founder, President and Interim Chief Executive Officer, Thomas Gad, will provide an overview and update on the Company's business at the virtual 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11, 2023, at 5:15 PM Eastern Standard Time. The presentation can be accessed via a live audio webcast.

Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.

Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Committee for Medicinal Products for Human use (“CHMP”) has adopted a negative opinion recommending a refusal of the marketing authorization for omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma in Europe.

The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update for naxitamab and the Company's SADA technology programs will be presented at the Company's R&D event, which will take place today at 9 a.m. Eastern Time.

Y-mAbs Announces Pipeline Update

eHealth

Eos Energy Enterprises

Rigel Pharmaceuticals

Vivani Medical Inc

Penny stocks to buy according to analysts in December 2022. The post 5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919%

NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its annual Research and Development Day in New York, NY on December 14, 2022, at 9:00 am ET. The event will feature presentations of the Company, its clinical development, and advanced product pipeline.

Y-mAbs to Host Annual Research and Development Day in New York

Boston, Massachusetts--(Newsfile Corp. - December 2, 2022) - Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ymab.What is this all about?On October 26, 2022, briefing documents posted to the U.S.

Y-mAbs Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Broker Wedbush has repeated a 'neutral' stance on biopharma Y-mAbs Therapeutics Inc (NASDAQ:YMAB) following news that the US Food and Drug Administration (FDA) has turned down the company's application concerning a treatment for a rare form of nerve cancer in pediatric patients. On December 1, the company that the regulator had issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine 131I-omburtamab (omburtamab) to treat CNS/leptomeningeal metastasis from neuroblastoma.

Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug application

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for the investigational medicine 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

OAKLAND, Calif.--( BUSINESS WIRE )--Y-mAbs Therapeutics, Inc. shares plummeted over 59% on October 31, 2022, after an FDA advisory committee voted against approving the company's neuroblastoma drug omburtamab on October 28, 2022, according to Marketwatch. Gibbs Law Group is investigating a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Lost Money in Y-mAbs Therapeutics, Inc.?

OAKLAND, Calif.--( BUSINESS WIRE )--Y-mAbs Therapeutics, Inc. shares plummeted over 59% on October 31, 2022, after an FDA advisory committee voted against approving the company's neuroblastoma drug omburtamab on October 28, 2022, according to Marketwatch. Previously, shares of Y-mAbs dropped 27% on October 26, 2022, after the FDA posted briefing documents in advance of the vote outlining “significant questions" as to the adequacy and control of the study Y-mAbs submitted regarding omburtamab. Gibbs Law Group is investigating a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Lost Money in Y-mABs Therapeutics, Inc.?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q3 2022 Earnings Conference Call November 8, 2022 4:00 PM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Edouard Mullarky - Guggenheim Securities Tessa Romero - JPMorgan Chase & Co. Sebastiaan van der Schoot - Kempen & Co. Joseph Thome - Cowen Operator Good afternoon, and welcome to the Y-mAbs Therapeutics, Inc. Earnings Conference Call for the Third Quarter of 2022. [Operator Instructions].

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Call Transcript

Ardelyx

23andMe

Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%

Los Angeles, California--(Newsfile Corp. - November 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ: YMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2022.

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

San Francisco, California--(Newsfile Corp. - November 4, 2022) - Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw.com 844-916-0895Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investigation: The investigation focuses on Y-mAbs' past assurances that its Biologics License Application ("BLA") for I-omburtamab for the treatment of central nervous system/leptomeningeal metastases in

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ymab.What is this all about?On October 26, 2022, briefing documents posted to the U.S.

Y-mAbs Therapeutics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ: YMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 8, 2022, at 4:00 p.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer and Vignesh Rajah, Chief Medical Officer.

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

Los Angeles, California--(Newsfile Corp. - November 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ: YMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) resulting from allegations that Y-mAbs may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – YMAB

Shares of Y-mAbs Therapeutics Inc. YMAB, +0.90% plunged 42.5% in premarket trading on Monday after several banks downgraded the company's stock and a Food and Drug Administration advisory committee voted against approval of the company's experimental treatment for neuroblastoma patients. The committee on Friday voted 16-0 that there wasn't enough evidence to say that omburtamab improves overall survival.

News for Y-Mabs Therapeutics Inc Stock (YMAB)